Exploring Novel Approaches in the Systemic Therapy of Low-grade Serous Carcinoma of the Ovary: a Literature Review

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Jun 5

PMID 38835797

Authors

Giovanna Vieira Giannecchini

Jesse Lopes da Silva

Gustavo de Oliveira Bretas

Alexssandra Lima Siqueira Dos Santos

Lais Fernandes Rodrigues Baltar

Andreia Cristina de Melo

Affiliations

Soon will be listed here.

Abstract

By presenting a comprehensive analysis of low-grade serous carcinomas (LGSCs), a subset of epithelial ovarian cancers, this review delves into their distinct molecular characteristics, clinicopathological features and systemic therapy options, emphasizing their differences from high-grade serous carcinomas (HGSCs). Notably, LGSCs exhibit prevalent RAS/RAF/MEK/MAPK pathway activation, KRAS and BRAF mutations, and infrequent p53 mutations. While chemotherapy is commonly employed, LGSCs display lower responsiveness compared to HGSCs. Hormone therapy, particularly endocrine maintenance therapy, is explored due to the higher estrogen receptor expression. Novel therapeutic approaches involving CDK4/6 inhibitors, MEK inhibitors, and antiangiogenic agents like bevacizumab are also investigated. Ongoing clinical trials are striving to enhance LGSC treatment strategies, offering valuable insights for future therapeutic advancements in this challenging ovarian cancer subtype.

References

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M . Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013; 14(3):236-43. PMC: 3596061. DOI: 10.1016/S1470-2045(12)70567-3. View

Malpica A, Deavers M, Lu K, Bodurka D, Atkinson E, Gershenson D . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4):496-504. DOI: 10.1097/00000478-200404000-00009. View

Bodurka D, Deavers M, Tian C, Sun C, Malpica A, Coleman R . Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2011; 118(12):3087-94. PMC: 11809296. DOI: 10.1002/cncr.26618. View

Kobel M, Kang E . The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel). 2022; 14(2). PMC: 8774015. DOI: 10.3390/cancers14020416. View

Gershenson D, Sun C, Lu K, Coleman R, Sood A, Malpica A . Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006; 108(2):361-8. DOI: 10.1097/01.AOG.0000227787.24587.d1. View

Markman M, Bundy B, Alberts D, Fowler J, Carson L, Wadler S . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the.... J Clin Oncol. 2001; 19(4):1001-7. DOI: 10.1200/JCO.2001.19.4.1001. View

Cannistra S, Matulonis U, Penson R, Hambleton J, Dupont J, Mackey H . Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25(33):5180-6. DOI: 10.1200/JCO.2007.12.0782. View

Wong K, Bateman N, Ng C, Tsang Y, Sun C, Celestino J . Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. J Transl Med. 2022; 20(1):606. PMC: 9758924. DOI: 10.1186/s12967-022-03820-x. View

Scott S, Fernandez M, Kim H, Elit L, Nourmoussavi M, Glaze S . Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. Gynecol Oncol. 2020; 157(1):36-45. DOI: 10.1016/j.ygyno.2020.01.021. View

10.

Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

11.

Therachiyil L, Anand A, Azmi A, Bhat A, Korashy H, Uddin S . Role of RAS signaling in ovarian cancer. F1000Res. 2022; 11:1253. PMC: 9669513. DOI: 10.12688/f1000research.126337.1. View

12.

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

13.

Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao D . Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29(2):218-24. DOI: 10.1097/01.pas.0000146025.91953.8d. View

14.

Moujaber T, Balleine R, Gao B, Madsen I, Harnett P, DeFazio A . New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocr Relat Cancer. 2021; 29(1):R1-R16. DOI: 10.1530/ERC-21-0191. View

15.

Di Lorenzo P, Conteduca V, Scarpi E, Adorni M, Multinu F, Garbi A . Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. Front Oncol. 2022; 12:970918. PMC: 9551309. DOI: 10.3389/fonc.2022.970918. View

16.

Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L . Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82. DOI: 10.1200/JCO.2007.12.1939. View

17.

Wong K, Tsang Y, Deavers M, C Mok S, Zu Z, Sun C . BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010; 177(4):1611-7. PMC: 2947258. DOI: 10.2353/ajpath.2010.100212. View

18.

Wang Y, Hong S, Mu J, Wang Y, Lea J, Kong B . Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study. J Oncol. 2019; 2019:8659754. PMC: 6425354. DOI: 10.1155/2019/8659754. View

19.

Grisham R, Slomovitz B, Andrews N, Banerjee S, Brown J, Carey M . Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023; 33(9):1331-1344. PMC: 10511962. DOI: 10.1136/ijgc-2023-004610. View

20.

Fader A, Java J, Krivak T, Bristow R, Tergas A, Bookman M . The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. Gynecol Oncol. 2013; 132(3):560-5. PMC: 4390028. DOI: 10.1016/j.ygyno.2013.11.016. View